GlassScriptPhysician profile
Jorge M Rodriguez
NPI 1952444648
$3,098.79
in general payments reported to CMS, 2019-2025
25 companies · $41.90 in 2025
The $41.90 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.62 · 2022: $934 · 2023: $779 · 2024: $1,331 · 2025: $41.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $811.55 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $790.07 | 2022-2024 | Vraylar, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.16 | 2022-2024 | Xifaxan |
| Pfizer INC. | $179.46 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $129.93 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $127.82 | 2023-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $105.05 | 2024 | |
| Exact Sciences Corporation | $103.48 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $88.77 | 2024-2025 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $54.83 | 2022 | |
| Glaxosmithkline, LLC. | $53.54 | 2023-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $47.36 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $44.11 | 2022 | |
| Intercept Pharmaceuticals, INC. | $35.44 | 2022 | |
| Celgene Corporation | $35.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $24.91 | 2024 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $23.99 | 2022 | |
| Redhill Biopharma INC. | $21.50 | 2022 | |
| Amgen INC. | $19.95 | 2022 | |
| Lucid Diagnostics INC. | $19.55 | 2023 | |
| Dexcom, INC. | $19.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.18 | 2022 | |
| Philips North America LLC | $15.91 | 2024 | (Ck7) Extended Holter |
| Shield Therapeutics INC | $15.31 | 2024 | |
| Vanda Pharmaceuticals INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.